<DOC>
	<DOC>NCT00599547</DOC>
	<brief_summary>The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation is a feasible and effective treatment for patients with primary myelofibrosis.</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients</brief_title>
	<detailed_description>The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors is a feasible and effective treatment for patients with primary myelofibrosis.</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Disease: Histologically proven Myelofibrosis with myeloid metaplasia/MMM defined as per the Italian Consensus Conference on MMM diagnosis with either primary MMM or secondary to Polycythaemia vera or essential thrombocythaemia with "intermediate risk" or "high risk" score according to the Lille Scoring System OR "low risk" score according to the Lille Scoring System with constitutional symptoms (fever, night sweat, weight loss &gt; 5% of body weight) OR "high risk" score according to the Cervantes score Age: Patients between 50 and 70 years of age and no limited life expectancy for other reasons than MMM Patients under 50 years of age who are not eligible for a standard myeloablative conditioning, (e.g., because of prior autologous stem cell, history of severe infections like fungal infections, history of cardiac toxicity or other reasons according to the treating physician) HLA compatible or identical donor, related or unrelated (one mismatch allowed) Written informed consent of the patient Positive search for bcrabl on blood. Serious irreversible renal, hepatic, pulmonary or cardiac disease Central nervous involvement Positive serology for HIV Pregnant or lactating women Patients with a lifeexpectancy of less than six months because of another debilitating disease Serious psychiatric or psychological disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>